GlassScriptPhysician profile
Michael S Tucker
NPI 1922033471
$2,371.73
in general payments reported to CMS, 2019-2025
29 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $188 · 2021: $194 · 2022: $406 · 2023: $359 · 2024: $717 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.45 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $287.76 | 2020-2024 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $218.59 | 2021-2025 | |
| Incyte Corporation | $215.25 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $180.92 | 2020-2025 | Winlevi, Absorica Ld, Blu-U |
| Regeneron Healthcare Solutions, INC. | $147.72 | 2021-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $146.92 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $133.58 | 2019-2024 | |
| Abbvie INC. | $128.23 | 2020-2024 | |
| Almirall LLC | $122.62 | 2021-2024 | Seysara |
| Allergan, INC. | $84.33 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.49 | 2019-2022 | |
| Genentech USA, INC. | $69.74 | 2019-2021 | |
| Leo Pharma INC. | $64.67 | 2019-2024 | Adbry |
| Ucb, INC. | $63.83 | 2023-2024 | Bimzelx |
| Pfizer INC. | $60.70 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $48.57 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $38.22 | 2019-2024 | Keytruda |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.26 | 2019 | |
| Dusa Pharmaceuticals, INC. | $37.03 | 2019 | |
| Dermavant Sciences, INC. | $30.95 | 2024 | Vtama |
| Kerecis Limited | $30.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Galderma Laboratories, L.P. | $26.81 | 2019-2020 | |
| Amgen INC. | $23.75 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $19.94 | 2023 | Valchlor |
| Phadia US INC. | $19.67 | 2024 | Immunocap |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.71 | 2025 | Caplyta |
| Vyne Pharmaceuticals INC. | $15.45 | 2020 | |
| Novo Nordisk INC | $13.77 | 2023 | Rybelsus, Ozempic |
| Dexcom, INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.